AstraZeneca's financial results were excellent last year despite a poor stock-market performance. The company faces some near-term headwinds, but this won't derail its long-term prospects ...

AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...

LONDON, March 21 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive ...

The 30-minute hearing in The Hague on Friday was procedural — a court officer informed Mr. Duterte of the charges, and Judge Iulia Motoc read him his rights and set a date for a hearing on Sept.

March 21 (UPI) --AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational pharmaceutical announced Friday. The investment will mark the ...

Step aside football, basketball and hockey, AstraZeneca is bringing its sports marketing efforts to the fastest-growing sport in America — pickleball. The pharma giant recently announced a partnership ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. AstraZeneca is bolstering its cell therapy capabilities, agreeing on Monday to pay up to $1 billion for a ...

Major news from Europe included earnings and investment updates. AstraZeneca (AZN) is expanding its footprint in China with an investment of $2.5B in Beijing over the next five years to build its ...